Gene Editing Returns to the IPO Market as Scribe Therapeutics Prices $129 Million Offering

The biotechnology IPO market added another name this week as Scribe Therapeutics (NASDAQ: SCTX) priced an upsized initial public offering, raising approximately $128.7 million and marking the first gene editing company to reach the public markets in more than two years.

The offering, priced at $15.00 per share, came at the top of the marketed range and included 8.58 million shares, with an additional private placement to existing partner Sanofi expected to add $7.5 million upon closing. The strong reception reflects improving investor appetite for biotechnology offerings and renewed interest in companies developing next-generation genetic medicines.

For investors, however, the significance extends beyond the IPO itself.

A Different Approach to CRISPR

While the first wave of CRISPR companies focused largely on permanently editing DNA to treat rare genetic disorders, Scribe is pursuing a different strategy aimed at far larger patient populations.

Its lead program, STX-1150, is designed to epigenetically silence the PCSK9 gene in the liver, lowering LDL cholesterol without permanently altering DNA. The company believes this approach could combine the durability associated with gene editing while avoiding permanent genomic changes.

Rather than targeting ultra-rare diseases, Scribe’s initial focus is atherosclerotic cardiovascular disease, one of the largest global markets in medicine. Elevated LDL cholesterol, lipoprotein(a), and triglycerides remain major drivers of cardiovascular risk, creating a potentially substantial commercial opportunity if durable one-time treatments can be successfully developed.

Early Stage, High Potential

Scribe remains an early clinical-stage company. STX-1150 recently received regulatory clearance to begin Phase 1 testing in Australia, making it one of the earliest-stage biotechnology companies to access the public markets during the current IPO cycle.

Its broader pipeline includes additional programs targeting lipoprotein(a) and APOC3, although those candidates are not expected to enter the clinic until 2027 or later.

The company’s platform has also attracted strategic validation through collaborations with Sanofi and Eli Lilly, with Sanofi participating in the financing through a concurrent private placement and Lilly remaining a significant shareholder.

A Window Reopens for Gene Editing

Scribe’s debut also serves as another indicator that the biotechnology financing environment continues to improve. According to industry reports, biotechnology has been one of the strongest-performing sectors for new public offerings in 2026, with multiple additional life sciences IPOs expected in the coming weeks.

For the gene editing sector specifically, Scribe represents more than another financing event. It signals that investors are again willing to fund companies pursuing next-generation CRISPR technologies, particularly those addressing large chronic diseases rather than exclusively rare genetic disorders.

As capital returns to the sector, the next milestone will be clinical execution. Scribe now has the resources to begin demonstrating whether its differentiated approach to gene editing can translate into meaningful clinical outcomes in one of medicine’s largest and most competitive markets.